Merkel cell

ASDS Recognizes 2022 Award Recipients at Annual Membership Meeting

Retrieved on: 
Monday, October 24, 2022
Resident, Virginia House of Delegates, Minnesota Department of Employment and Economic Development, Annual, Program, Delegate, University, Hair, Treatment, Health, Merkel cell, PATH (global health organization), Mohs surgery, Beauty, Skin care, Plasma, MBA, Annual general meeting, FRCPC, Knowledge, Blemish (album), Incidence, Lecture, Medicine, Skin, GLOBE, African, Leadership, Time, Washington Institute, ASDS, Society, Research, Cutting edge, Georgetown University Medical Center, Instagram, HIV, House, Skin cancer, Disease, JD, Education, Merkel-cell carcinoma, Partnership, Human, Systematic review, Social media, Faculty, Cross, Dentistry, Veterinary medicine, Pharmaceutical industry, Hospital, Dermatology, DRS, MD, Patient

Rolling Meadows, IL, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Top dermatologists were recognized at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Denver, Colorado, during the Annual Membership Meeting on Saturday, Oct. 8.

Key Points: 
  • Rolling Meadows, IL, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Top dermatologists were recognized at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Denver, Colorado, during the Annual Membership Meeting on Saturday, Oct. 8.
  • ASDS / ASDSA Staff For the contributions ASDS / ASDSA staff members make every day that support the success of the organization.
  • He accepted his award at the Annual ASDS Gala on Saturday, Oct. 8.
  • Sean Wu, MD, received the highest scoring for his outstanding ASDS Annual Meeting abstract submission, Vision Loss After Platelet-Rich Plasma Injection: A Systematic Review of Medical Literature.

2021 Global Merkel Cell Carcinoma Pipeline Insight Report - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 21, 2021
Pharmaceutical, Health, Oncology, News, Clinical trial, TLR9, MCC, FDA, Route of administration, CSCC, Phase, HDAC, Neoplasm, Merck, Merkel cell, Discovery, ROA, Safety, Therapy, Injection, Pharmacokinetics, Tumor microenvironment, Route, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, II, Limited partnership, Patient, Administration, Pharmaceutical industry, Merkel-cell carcinoma, Angela Merkel

The "Merkel Cell Carcinoma - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Merkel Cell Carcinoma - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Merkel Cell Carcinoma pipeline landscape.
  • This segment of the Merkel Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • Merkel Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Sensei Biotherapeutics Reports First Quarter 2021 Results and Provides Business Update

Retrieved on: 
Wednesday, May 12, 2021
Health sciences, Politicians, Life sciences, Breakthrough therapy, Durvalumab, XC2, Serbian Progressive Party, Angela Merkel, Merkel cell, AstraZeneca

Sensei has concluded its clinical trial collaboration with AstraZeneca for durvalumab (Imfinzi\xc2\xae).

Key Points: 
  • Sensei has concluded its clinical trial collaboration with AstraZeneca for durvalumab (Imfinzi\xc2\xae).
  • Sensei expects the current cash balance to fund operations at least into the second half of 2023.\nResearch and Development (R&D) Expenses\xc2\xa0\xe2\x80\x93 R&D expenses were $3.4 million for the quarter ended March 31, 2021, compared to $2.2 million for the quarter ended March 31, 2020.
  • Additional ImmunoPhage program is SNS-401, an ImmunoPhage cocktail in preclinical development for the treatment of Merkel Cell Carcinoma.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.